The list of game-changing opportunities never ends. In fact, in today’s environment — where information, ideas, and technology are spreading at the speed of light — I think the opportunities are greater than ever.

Think of everything we know today that has changed over just a few years…

“Zoom” meetings have become the norm… the cord-cutting trend has invaded living rooms everywhere… Electric vehicles have become commercially available… We’re on the cusp of curing genetic diseases with DNA sequencing… Alternative energy captured the nation’s interest… Heck, scientists even made a breakthrough in nuclear fusion!

I could go on and on. And I bet you wouldn’t have thought half of this was possible a little more than a decade ago.

But over at Capital Wealth Letter, we make it our business to investigate game-changing technologies and research key trends. And each year, we release our findings annually in a special report that individual investors can use to potentially make a killing…

To be sure, not all our predictions will come true. Some of the stocks mentioned in our report will lose money. That goes with the territory when you’re looking for game-changers. And that’s okay. The returns could be spectacular if we can uncover just a handful of these gems before the rest of the crowd.

We’ve covered some of the highlights of our predictions report already. But today, I want to share more details on one of this year’s predictions with you…

Prediction #2: The First Cancer Vaccine Will Be Developed

Vaccines save countless lives every year. The smallpox virus has been completely eradicated, for example. Meanwhile, polio, measles, and other childhood diseases have been drastically reduced.

Science has struggled for decades to develop effective treatments for non-infectious killers like cancer. The idea of a cancer vaccine sounded good in theory. But the thing is, it’s no longer just a theory.

This hurdle could be overcome soon. Currently, scientists are working on a skin cancer vaccine that will be personalized for individual patients. If it bears fruit, high-risk melanoma patients could be treated with a single injection.

Melanoma is the deadliest form of skin cancer, killing more than 7,000 people a year in the United States alone. Soon, instead of covering yourself in sunscreen and protective clothing, you could be inoculated against getting skin cancer in the first place.

The promising thing about this treatment is that it’s based on the same mRNA technology used to create the revolutionary Covid-19 vaccines. That’s why it’s called a vaccine, even though it targets a non-contagious disease.

It’s a joint effort between two high-profile biotech companies — an innovative smaller player and a larger Big Pharma partner with extensive resources. I can’t reveal the name of both of them out of fairness to my premium subscribers.

But I will reveal one of them right now and explain how this works — and why it’s a big deal.

The Big Pharma Pick

The first pick is global pharmaceutical giant Merck (NYSE: MRK).

Merck develops and manufactures a wide range of prescription drugs and vaccines for a variety of medical conditions. It also conducts research and development to discover new treatments and therapies, which they bring to market through clinical trials and regulatory approval processes.

Some of the company’s most successful vaccines and drugs include:

• Keytruda: an immunotherapy drug that is used to treat a variety of cancers, including melanoma, lung cancer, and head and neck cancer.
• Januvia: a drug used to treat type 2 diabetes by helping lower blood sugar levels.
• Isentress: a drug used to treat HIV infection and AIDS.
• Propecia: a drug used to treat male pattern hair loss.
• Gardasil: a vaccine used to prevent certain types of human papillomavirus (HPV).
• Proquad: vaccine used to prevent measles, mumps, rubella, and chickenpox.
• Pneumovax: a vaccine used to prevent pneumococcal disease, which can cause serious infections such as pneumonia, meningitis, and blood infections.

Merck has a diverse portfolio of products used to treat a wide range of medical conditions. These drugs and vaccines billions in sales last year, profits, and cash flow.

But what are the catalysts for future growth in Merck’s share price? What I found is pretty exciting…

Merck has partnered with our other pick and is developing a cancer vaccine.

mRNA: A Revolutionary Vaccine Technology

This partnership originally started in April 2020 in response to the Covid-19 pandemic. Under the partnership, Merck agreed to manufacture this company’s vaccine, using its expertise and resources in large-scale production.

This vaccine is based on a new technology called messenger RNA (mRNA).

Conventional vaccines are produced using weakened forms of a virus, but an mRNA vaccine uses the virus’s genetic code instead. It is injected into the body, entering cells and telling them to create antigens to bolster the immune system.

Because no virus is needed to create an mRNA vaccine, it can be produced faster and cheaper than traditional vaccines. It’s also safer than using a live virus because there is no risk of infection.

The smaller company mentioned in our report has developed a novel platform for creating mRNA-based therapies. It has been used to create several promising candidates for the treatment of various diseases — and, most recently, cancer.

Simply put, these two companies are focusing on using that same technology to develop a cancer vaccine. More specifically, a personalized cancer vaccine (“PCV”). The graphic below (courtesy of our other pick), explains the basics…

The implications are huge if this works. So let me give you a rundown…

The Holy Grail Of Medicine?

You might think that all cancer is the same. For instance, you might believe melanoma cancer in one patient is the same as the other. And on the surface, it is. Melanoma is melanoma.

But have you ever wondered why one cancer patient reacts better to treatment compared with another? Doctors have certainly been puzzled by this… and thanks to some scientific breakthroughs, we have an answer. We now know that each cancer is different — no two are the same. That’s because cancer cells have genetic mutations that make them unique.

Doctors can now get the exact gene code in a patient’s body. Once they have the exact cancer type, they can manufacture a specific PCV for that cancer and begin treatment.

Here’s how this it works…

Our smaller company’s messenger RNA vaccine triggers the immune system to deploy killer T cells targeting specific mutations of a patient’s tumors. Meanwhile, Merk’s monoclonal antibody, administered as an injection, prevents cell proteins from stopping those T cells from going on the attack.

Here’s the crazy thing about this potential cancer vaccine that has investors salivating…

Once they have this code, they fine-tune their PCV. It currently takes eight weeks to manufacture a specific PCV, but the company hopes to reduce this time in half.

Once they have the patient’s unique cancer-fighting cocktail, they begin treatment.

This game-changing vaccine — being developed in a joint effort — just completed the second of three trials. According to a joint statement, the companies “plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types.”

This has investors excited. And it has created some nice tailwinds for Merck.

Action To Take

The market for mRNA-based therapies is exploding right now. That’s because mRNA-based therapies have the potential to revolutionize the way that diseases are treated.

This technology can potentially be applied to a wide range of diseases. If it successfully brings its therapies to market, it could generate significant revenue and profits for shareholders.

Merck is a respected, well-known player in the pharmaceutical space. It’s obviously the safer play in this partnership. But it could still see significant upside if this treatment passes Phase III trials. Our other pick, meanwhile, is riskier — but could have even more upside.

Either way you choose to invest, we think the time to jump on it is now, before the results are released.

Go here to get the rest of the details on our predictions for 2023 now.